{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:10:20Z","timestamp":1778584220191,"version":"3.51.4"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Lynch syndrome (LS) is a cancer susceptibility syndrome characterized by a high risk table of multiple cancer types, most commonly endometrial cancer (EC). Currently, universal tumor screening to identify LS in women with EC remains uncommon. This study aimed to determine the incidence of LS and its molecular landscape by conducting a retrospective analysis of a cohort of patients with EC in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 220 patients with EC were identified from the Hospital between March 2022 and May 2025. Germline variants in LS-associated genes (\n                      <jats:italic toggle=\"yes\">MLH1, PMS2, MSH2, MSH6<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">EPCAM<\/jats:italic>\n                      ) and molecular subtypes [\n                      <jats:italic toggle=\"yes\">POLE, TP53<\/jats:italic>\n                      genes, and microsatellite instability (MSI)] were analyzed using next-generation sequencing (NGS). Mismatch repair (MMR) proteins were screened by immunohistochemistry (IHC). Tumors with loss of MLH1 or MLH1\/PMS2 protein expression were tested for MLH1 promoter methylation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 220 cases, 16 (7.3%) had a pathogenic germline variant in MMR genes, with the majority identified in MSH6 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =\u00a07), followed by\n                      <jats:italic toggle=\"yes\">MLH1<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =\u00a03),\n                      <jats:italic toggle=\"yes\">PMS2<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =\u00a03), and\n                      <jats:italic toggle=\"yes\">MSH2<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =\u00a03). A total of 22 EC tumors (10.0%) carried a variant of uncertain significance in the LS-associated genes. Our results revealed that the percentages of the different molecular subtypes were POLE-mutated (POLEmut; 10.9%), mismatch repair deficient (MMRd; 25.5%), p53 abnormal (p53abn; 8.6%), and no specific molecular profile (NSMP; 55.0%). Ten \u201cmultiple-classifier\u201d tumors (4.5% of the total cases) were identified. These included five MMRd-p53abn, four POLEmut-p53abn, and one POLE-MMRd.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study confirms the effectiveness of NGS in identifying germline variants within a Chinese cohort of patients with EC, revealing an LS prevalence of 7.3%. Relying solely on MMR-IHC or MSI testing could lead to missed diagnoses of LS. Our findings contribute to a better understanding of the mutational landscape and prevalence of LS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003945","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T18:01:20Z","timestamp":1763402480000},"page":"3154-3164","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Universal screening for Lynch syndrome and molecular classification of patients with endometrial cancer"],"prefix":"10.1097","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-4488","authenticated-orcid":false,"given":"Guangwei","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Zhengzhou Key Laboratory of Gynecological Disease\u2019s Early Diagnosis, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Zhengzhou Key Laboratory of Gynecological Disease\u2019s Early Diagnosis, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushan","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Zhengzhou Key Laboratory of Gynecological Disease\u2019s Early Diagnosis, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tengfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Zhengzhou Key Laboratory of Gynecological Disease\u2019s Early Diagnosis, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Zhengzhou Key Laboratory of Gynecological Disease\u2019s Early Diagnosis, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianxu","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China"},{"name":"Zhengzhou Key Laboratory of Gynecological Disease\u2019s Early Diagnosis, Zhengzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"R1-20260512","doi-asserted-by":"crossref","first-page":"573\u201380","DOI":"10.1016\/j.ygyno.2021.01.036","article-title":"Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019","volume":"161","author":"Gu","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R2-20260512","first-page":"17\u201348","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R3-20260512","first-page":"67\u201373","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"R4-20260512","doi-asserted-by":"crossref","first-page":"712\u201320","DOI":"10.1016\/j.ygyno.2020.09.039","article-title":"Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening","volume":"159","author":"Carr","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R5-20260512","doi-asserted-by":"crossref","first-page":"7\u201317","DOI":"10.1002\/ijc.33763","article-title":"Endometrial cancer in Lynch syndrome","volume":"150","author":"Zhao","year":"2022","journal-title":"Int J Cancer"},{"key":"R6-20260512","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40880-019-0388-2","article-title":"Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China","volume":"39","author":"Chao","year":"2019","journal-title":"Cancer Commun (Lond)"},{"key":"R7-20260512","doi-asserted-by":"crossref","first-page":"458\u201367","DOI":"10.20892\/j.issn.2095-3941.2019.0295","article-title":"Identification of novel Lynch syndrome mutations in Chinese patients with endometriod endometrial cancer","volume":"17","author":"Ren","year":"2020","journal-title":"Cancer Biol Med"},{"key":"R8-20260512","doi-asserted-by":"crossref","first-page":"518\u201331","DOI":"10.1002\/path.5422","article-title":"Molecular pathology of Lynch syndrome","volume":"250","author":"Cerretelli","year":"2020","journal-title":"J Pathol"},{"key":"R9-20260512","first-page":"100082","article-title":"Transparency in the reporting of Artificial Intelligence \u2013 the TITAN Guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R10-20260512","doi-asserted-by":"crossref","first-page":"1440971","DOI":"10.3389\/fgene.2024.1440971","article-title":"The clinical utility of next generation sequencing in endometrial cancer: focusing on molecular subtyping and lynch syndrome","volume":"15","author":"Guo","year":"2024","journal-title":"Front Genet"},{"key":"R11-20260512","doi-asserted-by":"crossref","first-page":"385\u201399","DOI":"10.1002\/cncr.35030","article-title":"Characterization of mismatch-repair\/microsatellite instability-discordant endometrial cancers","volume":"130","author":"Riedinger","year":"2024","journal-title":"Cancer"},{"key":"R12-20260512","doi-asserted-by":"crossref","first-page":"2167\u201380","DOI":"10.1038\/s41436-019-0536-8","article-title":"The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis","volume":"21","author":"Ryan","year":"2019","journal-title":"Genet Med"},{"key":"R13-20260512","doi-asserted-by":"crossref","first-page":"3172\u201383","DOI":"10.1002\/cncr.32203","article-title":"Universal endometrial cancer tumor typing: how much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?","volume":"125","author":"Kahn","year":"2019","journal-title":"Cancer"},{"key":"R14-20260512","first-page":"147\u201358","article-title":"The genetic basis of Lynch syndrome and its implications for clinical practice and risk management","volume":"7","author":"Cohen","year":"2014","journal-title":"Appl Clin Genet"},{"key":"R15-20260512","doi-asserted-by":"crossref","first-page":"7810\u201317","DOI":"10.1158\/0008-5472.CAN-06-1114","article-title":"Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients","volume":"66","author":"Hampel","year":"2006","journal-title":"Cancer Res"},{"key":"R16-20260512","doi-asserted-by":"crossref","first-page":"229\u201338","DOI":"10.1016\/j.ygyno.2020.07.013","article-title":"Lynch syndrome identification in a Brazilian cohort of endometrial cancer screened by a universal approach","volume":"159","author":"Rosa","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R17-20260512","doi-asserted-by":"crossref","first-page":"106\u201314","DOI":"10.1016\/j.jmoldx.2023.10.005","article-title":"MLH1 promotor hypermethylation in colorectal and endometrial carcinomas from patients with lynch syndrome","volume":"26","author":"Helderman","year":"2024","journal-title":"J Mol Diagn"},{"key":"R18-20260512","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/s12885-018-4489-0","article-title":"Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review","volume":"18","author":"Yokoyama","year":"2018","journal-title":"BMC Cancer"},{"key":"R19-20260512","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.3390\/ijms22168627","article-title":"Classification of MSH6 variants of uncertain significance using functional assays","volume":"22","author":"Frederiksen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R20-20260512","doi-asserted-by":"crossref","first-page":"385\u201393","DOI":"10.1007\/s10689-016-9882-8","article-title":"Update on Lynch syndrome genomics","volume":"15","author":"Peltom\u00e4ki","year":"2016","journal-title":"Fam Cancer"},{"key":"R21-20260512","doi-asserted-by":"crossref","first-page":"4128\u201333","DOI":"10.1073\/pnas.1520813113","article-title":"Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants","volume":"113","author":"Houlleberghs","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R22-20260512","doi-asserted-by":"crossref","first-page":"e70026","DOI":"10.1002\/mgg3.70026","article-title":"Reclassification of two MLH1 variants of uncertain significance utilizing clinical and functional data","volume":"12","author":"Frederiksen","year":"2024","journal-title":"Mol Genet Genomic Med"},{"key":"R23-20260512","doi-asserted-by":"crossref","first-page":"e0304141","DOI":"10.1371\/journal.pone.0304141","article-title":"Functional analysis of MMR gene VUS from potential Lynch syndrome patients","volume":"19","author":"Mahdouani","year":"2024","journal-title":"PLoS One"},{"key":"R24-20260512","doi-asserted-by":"crossref","first-page":"405\u201324","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"R25-20260512","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.3390\/cancers15245762","article-title":"Prevalence of variants of uncertain significance in patients undergoing genetic testing for hereditary breast and ovarian cancer and Lynch syndrome","volume":"15","author":"Chrysafi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R26-20260512","doi-asserted-by":"crossref","first-page":"588\u201395","DOI":"10.1016\/j.ygyno.2017.07.003","article-title":"Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival","volume":"146","author":"Cosgrove","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R27-20260512","doi-asserted-by":"crossref","first-page":"1212\u201320","DOI":"10.1093\/jnci\/djab029","article-title":"Prevalence and prognosis of Lynch syndrome and sporadic mismatch repair deficiency in endometrial cancer","volume":"113","author":"Post","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"R28-20260512","doi-asserted-by":"crossref","first-page":"4473\u201381","DOI":"10.1158\/1078-0432.CCR-16-2655","article-title":"Immune microenvironment in microsatellite-instable endometrial cancers: hereditary or sporadic origin matters","volume":"23","author":"Pakish","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R29-20260512","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.3802\/jgo.2024.35.e103","article-title":"Unveiling pembrolizumab effectiveness in diverse subtypes of MSI-high endometrial cancers","volume":"35","author":"Ozawa","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"R30-20260512","doi-asserted-by":"crossref","first-page":"1808\u201325","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"R31-20260512","first-page":"1357\u201372","article-title":"Immune checkpoint inhibitors for patients with mismatch repair deficient or microsatellite instability-high advanced cancers: a meta-analysis of phase I-III clinical trials","volume":"111","author":"Wang","year":"2025","journal-title":"Int J Surg"},{"key":"R32-20260512","doi-asserted-by":"crossref","first-page":"1180\u201388","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"R33-20260512","doi-asserted-by":"crossref","first-page":"9\u201316","DOI":"10.1016\/j.ygyno.2025.05.005","article-title":"Pragmatic preoperative molecular classification of endometrial cancers; replacing POLE sequencing with hormone receptor staining","volume":"198","author":"Berg","year":"2025","journal-title":"Gynecol Oncol"},{"key":"R34-20260512","doi-asserted-by":"crossref","first-page":"103710","DOI":"10.1016\/j.esmoop.2024.103710","article-title":"Identification of molecular subtypes for endometrial carcinoma using a 46-gene next-generation sequencing panel: a retrospective study on a consecutive cohort","volume":"9","author":"Guo","year":"2024","journal-title":"ESMO Open"},{"key":"R35-20260512","doi-asserted-by":"crossref","first-page":"155152","DOI":"10.1016\/j.prp.2024.155152","article-title":"Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population","volume":"254","author":"Kang","year":"2024","journal-title":"Pathol Res Pract"},{"key":"R36-20260512","doi-asserted-by":"crossref","first-page":"312\u201322","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"R37-20260512","doi-asserted-by":"crossref","first-page":"229\u201338","DOI":"10.1136\/ijgc-2023-004864","article-title":"Clinicopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review","volume":"34","author":"De Vitis","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"R38-20260512","doi-asserted-by":"crossref","first-page":"1646\u201355","DOI":"10.1111\/cas.16121","article-title":"Clinical features and impact of p53 status on sporadic mismatch repair deficiency and Lynch syndrome in uterine cancer[J]","volume":"115","author":"Kato","year":"2024","journal-title":"Cancer Sci"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:20:26Z","timestamp":1778581226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003945","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"2025-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}